Want to see IN:DIVISLAB full AI Analyst Report?
DIVISLAB Stock Chart & Stats
₹7246.65
₹165.50(2.28%)
At close: 4:00 PM EDT
₹7246.65
₹165.50(2.28%)
Day’s Range― - ―
52-Week Range₹5,637.50 - ₹8,087.00
Previous CloseN/A
Volume544.67K
Average Volume (3M)6.36K
Market Cap
₹2.14T
Enterprise Value₹1.54M
Total Cash (Recent Filing)₹34.14B
Total Debt (Recent Filing)₹70.00M
Price to Earnings (P/E)83.2
Beta0.81
Next Earnings
Nov 09, 2026EPS Estimate
29.49Next Dividend Ex-DateN/A
Dividend Yield0.37%
Share Statistics
EPS (TTM)96.77
Shares Outstanding265,468,570
10 Day Avg. Volume6,055
30 Day Avg. Volume6,356
Financial Highlights & Ratios
PEG Ratio3.57
Price to Book (P/B)9.42
Price to Sales (P/S)14.95
P/FCF Ratio317.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹7,717.50Price Target Upside6.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)116.12
Revenue Forecast (FY)₹122.70B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetNegligible leverage and steadily expanding equity provide durable financial flexibility. A conservative balance sheet supports capital allocation through cycles, funds compliance and capacity investments without heavy external financing, and reduces solvency risk over a multi‑quarter horizon.
Improving Operating Cash GenerationRising operating cash flow across 2024–2026 signals growing internal cash generation ability. Strong cash from operations supports reinvestment in facilities and CDMO projects, funds working capital, and lowers reliance on external funding, enhancing durability of growth initiatives.
High Margins And Revenue ReboundSustained high gross and healthy net margins indicate manufacturing scale, process efficiency and pricing power in APIs/CDMO. Combined with revenue recovery and rising net income, this positions the firm to generate persistent operating profits and reinvest in higher‑value projects.
Bears Say
Uneven Free Cash Flow ConversionVolatile free cash flow versus operating cash suggests swings from capex or working capital that can compress distributable cash. This variability complicates long‑term planning, may constrain shareholder returns, and increases sensitivity to investment timing over coming quarters.
Profitability NormalizationA step‑down from the 2021–22 margin peak implies past exceptional profitability is not fully repeatable. Structural pressure or mix shifts may limit upside to margins and returns on capital, meaning future earnings growth must rely more on volume or higher‑value products.
Structural Exposure To Demand & RegulationBusiness is structurally tied to a few large customers, product lifecycle timing and regulatory approvals. That dependency can cause durable revenue swings when customers change sourcing, patents expire or approvals shift, raising execution and utilization risks over months.
Divi's Laboratories Limited News
DIVISLAB FAQ
What was Divi's Laboratories Limited’s price range in the past 12 months?
Divi's Laboratories Limited lowest stock price was ₹5637.50 and its highest was ₹8087.00 in the past 12 months.
What is Divi's Laboratories Limited’s market cap?
Divi's Laboratories Limited’s market cap is ₹2.14T.
When is Divi's Laboratories Limited’s upcoming earnings report date?
Divi's Laboratories Limited’s upcoming earnings report date is Nov 09, 2026 which is in 98 days.
How were Divi's Laboratories Limited’s earnings last quarter?
Divi's Laboratories Limited released its earnings results on Aug 01, 2026. The company reported ₹33.98 earnings per share for the quarter, beating the consensus estimate of ₹24.677 by ₹9.303.
Is Divi's Laboratories Limited overvalued?
According to Wall Street analysts Divi's Laboratories Limited’s price is currently Undervalued.
Does Divi's Laboratories Limited pay dividends?
Divi's Laboratories Limited pays a Annually dividend of ₹30 which represents an annual dividend yield of 0.37%. See more information on Divi's Laboratories Limited dividends here
What is Divi's Laboratories Limited’s EPS estimate?
Divi's Laboratories Limited’s EPS estimate is 29.49.
How many shares outstanding does Divi's Laboratories Limited have?
Divi's Laboratories Limited has 265,468,570 shares outstanding.
What happened to Divi's Laboratories Limited’s price movement after its last earnings report?
Divi's Laboratories Limited reported an EPS of ₹33.98 in its last earnings report, beating expectations of ₹24.677. Following the earnings report the stock price went up 4.889%.
Which hedge fund is a major shareholder of Divi's Laboratories Limited?
Currently, no hedge funds are holding shares in IN:DIVISLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Divi's Laboratories Limited
Divi's Laboratories Limited, established in 1990 and based in Hyderabad, India, operates globally in the production and distribution of generic active pharmaceutical ingredients (APIs), intermediate chemicals, and nutraceuticals. The company's market footprint encompasses India, the United States, Asia, Europe, and other international regions. In addition to its core product lines, Divi's offers bespoke synthesis services for APIs and intermediates. It also provides a diverse range of carotenoids and markets various vitamins, catering to the nutritional, pharmaceutical, food and beverage, and animal feed industries. The firm was formerly known as Divi's Research Center before rebranding to Divi's Laboratories Limited in 1994.
DIVISLAB Stock 12 Month Forecast
Average Price Target
₹7,717.50
▲(6.50% Upside)
Technical Analysis
Aurobindo Pharma Ltd
―
Dr. Reddy's Laboratories Ltd.
―
Granules India Limited
―
Laurus Labs Ltd.
―
Neuland Laboratories Ltd.
―







